TABLE 2.
Oral temperature (OT) and vigilance (VT) values measured before (BRET) and after (ARET) the running exercise test (RET) following melatonin (MEL) or placebo (PLA) ingestion.
| PLA | MEL | Effects | |||||
|---|---|---|---|---|---|---|---|
| BRET | ARET | BRET | ARET | Condition | Exercise | Interaction | |
| OT (°C) | 36.61 ± 0.19 | 37.80 ± 0.24a | 36.51 ± 0.35 | 37.58 ± 0.19 ab | F(1.12) = 6.51; p < 0.05; η2 p = 0.35 | F(1.12) = 731.48; p < 0.001; η2 p = 0.98 | F(1.12) = 2.4; p > 0.05; η2 p = 0.17 |
| VT (AU) | 67.38 ± 11.43 | 71.92 ± 10.06 | 64.85 ± 9.97 | 66.54 ± 11.63 | F(1.12) = 9.78; p < 0.05; η2 p = 0.45 | F(1,12) = 2.99; p > 0.05; η2 p = 0.20 | F(1,12) = 0.49; p > 0.05; η2 p = 0.04 |
a
significant difference in comparison with values measured before the RET.
b
significant difference in comparison with values measured in PLA condition.